How do you manage partial response following 6 cycles of carboplatin/paclitaxel/immunotherapy for advanced endometrial cancer with persistent peritoneal disease when surgical debulking is not an option?

A lot depends on the molecular makeup of the endometrial cancer. I would absolutely continue for dMMR or even TP53mut, but IO is unlikely to work in the NSMP subgroup. In that scenario, you could continue to progression or look at other markers, i.e., HER2. Trial is the next best option, and standar...